title: Fc engineering of antibodies and antibody derivatives by primary sequence alteration and their functional characterization.
abstract: Therapeutic antibodies used in the treatment of cancer patients are able to mediate diverse effector mechanisms. Dependent on tumor entity, localization, and tumor burden different effector mechanisms may contribute to the in vivo antitumor activity to a variable degree. Especially Fc-mediated effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) have been suggested as being important for the in vivo activity of therapeutic antibodies like rituximab or trastuzumab. In recent years, several strategies have been pursued to further optimize the cytotoxic potential of monoclonal antibodies by modifying their Fc part (Fc engineering) with the ultimate goal to enhance antibody therapy.Since Fc engineering approaches are applicable to any Fc-containing molecule, strategies to enhance CDC or ADCC activity of full antibodies or scFv-Fc fusion proteins by altering the primary Fc sequence are described.
authors: Division for Stem Cell Transplantation and Immunotherapy, Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein, Kiel, Germany.
authors: Stefanie
authors: S
authors: Derer
authors: Christian
authors: C
authors: Kellner
authors: Thies
authors: T
authors: Rösner
authors: Katja
authors: K
authors: Klausz
authors: Pia
authors: P
authors: Glorius
authors: Thomas
authors: T
authors: Valerius
authors: Matthias
authors: M
authors: Peipp
mesh_terms: D000906:Antibodies / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000276:immunology*; D006801:Humans; D007141:Immunoglobulin Fc Fragments / Q000276:immunology*
chemical_list: D000906:Antibodies; D000911:Antibodies, Monoclonal; D007141:Immunoglobulin Fc Fragments